Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00189917
Status:
COMPLETED
Last Update Posted:
2019-01-10
First Post:
2005-09-11
Brief Title:
Safety Tolerability and Immune Response of IMVAMUNE MVA-BNSmallpox Vaccine in Patients With Atopic Disorders
Sponsor:
Bavarian Nordic
Organization:
Bavarian Nordic
Study Overview
Official Title:
An Open-label Controlled Phase I Pilot Study to Evaluate Safety and Immunogenicity of MVA-BN Smallpox Vaccine in 18-40 Year Old Vaccinia-naïve Subjects With Atopic Disorders
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in populations with atopic disorders
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| N01-AI-30016 | OTHER_GRANT | NIAID | None |